The European Commission has granted Marketing Authorization (MA) for Incresync (alogliptin with pioglitazone), from Takeda, for the treatment of Type...
On 25 July 2013, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for Incresync, 12.5...
The EMA's Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions for updates to the Summary of...
The FDA has issued a warning to healthcare providers and patients about concerns over severe and disabling joint pain associated...